Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine — United States, 2003–2018

About this resource:

Non-Systematic Review

Source: Centers for Disease Control and Prevention

Last Reviewed: April 2021

Workgroups: Immunization and Infectious Diseases Workgroup

In this report, the Centers for Disease Control and Prevention (CDC) summarizes data that show a decline in vaccine-type prevalence of human papillomavirus (HPV) among young females after introduction of HPV vaccination in 2006.

Nationally representative data through 2018 indicate that HPV vaccine-type prevalence continues to decline among females age 14 to 19 years (88 percent) and age 20 to 24 years (81 percent), compared with before vaccination. The findings also show evidence of indirect protection of unvaccinated females through herd effects in these age groups.

CDC’s findings highlight that HPV vaccination is a critical prevention tool against HPV infection, anogenital warts, and HPV-attributable precancers and cancers. HPV vaccination is highly effective and is recommended routinely at age 11 to 12 years and through age 26 years for people not already vaccinated.

Read more about this resource

Objectives related to this resource (2)

Increase the proportion of adolescents who get recommended doses of the HPV vaccine — IID‑08
Improving
Reduce infections of HPV types prevented by the vaccine in young adults — IID‑07
Baseline only

Suggested Citation

1.

Rosenblum HG, Lewis RM, Gargano JW, et al. (2021). Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018. Retrieved from https://www.cdc.gov/mmwr/volumes/70/wr/mm7012a2.htm?s_cid=mm7012a2_w.